U.S. Markets open in 4 hrs 35 mins

CytRx to initiate Phase 2b trial in brain cancer in 2H

The company said, “We are making preparations to begin in the coming months two late-stage clinical trials with aldoxorubicin, our improved version of the widely used chemotherapeutic doxorubicin, and expect to report data in the second half of 2013 from our global Phase 2b clinical trial testing aldoxorubicin head-to-head against doxorubicin as a first-line therapy for soft tissue sarcomas. We plan to initiate a Phase 2b clinical trial later this year in patients with advanced, relapsed glioblastoma , or brain cancer...Our global pivotal Phase 3 trial is expected to commence in the first quarter of 2014. This clinical trial will evaluate aldoxorubicin as a treatment for patients with soft tissue sarcomas which have progressed following prior treatment with chemotherapy."